|
1
|
Asrani SK and Kamath PS: Natural history
of cirrhosis. Curr Gastroenterol Rep. 15(308)2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schuppan D and Afdhal NH: Liver cirrhosis.
Lancet. 371:838–851. 2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ginès P, Krag A, Abraldes JG, Solà E,
Fabrellas N and Kamath PS: Liver cirrhosis. Lancet. 398:1359–1376.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kumar R, Kumar S and Prakash SS:
Compensated liver cirrhosis: Natural course and disease-modifying
strategies. World J Methodol. 13:179–193. 2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
D'Amico G and Perricone G: Prediction of
decompensation in patients with compensated cirrhosis: Does
etiology matter? Curr Hepatol Rep. 18:144–156. 2019.
|
|
6
|
Moon AM, Singal AG and Tapper EB:
Contemporary epidemiology of chronic liver disease and cirrhosis.
Clin Gastroenterol Hepatol. 18:2650–2666. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Devarbhavi H, Asrani SK, Arab JP, Nartey
YA, Pose E and Kamath PS: Global burden of liver disease: 2023
update. J Hepatol. 79:516–537. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
D'Amico G, Garcia-Tsao G and Pagliaro L:
Natural history and prognostic indicators of survival in cirrhosis:
A systematic review of 118 studies. J Hepatol. 44:217–231.
2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang Y, Wang M, Liu C, Hao M, Wang W, Li
Y, Shi J, Jia X, Zhang X and Dang S: Global burden of liver
cirrhosis 1990-2019 and 20 years forecast: Results from the global
burden of disease study 2019. Ann Med. 56(2328521)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wu XN, Xue F, Zhang N, Zhang W, Hou JJ, Lv
Y, Xiang JX and Zhang XF: Global burden of liver cirrhosis and
other chronic liver diseases caused by specific etiologies from
1990 to 2019. BMC Public Health. 24(363)2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Asrani SK, Devarbhavi H, Eaton J and
Kamath PS: Burden of liver diseases in the world. J Hepatol.
70:151–171. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Flores-Garcia NC, Dirac M, Han H and
Kershenobich-Stalnikowitz D: Burden of disease due to liver
cirrhosis in Mexico. Gac Med Mex. 159:494–501. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Servin-Rojas M, Olivas-Martinez A,
Toapanta-Yanchapaxi L and García-Juárez I: Liver transplantation in
Mexico. Clin Liver Dis (Hoboken). 19:53–58. 2022.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
World Health Organization (WHO). Leading
causes of death, Mexico. WHO, Geneva, 2024. https://data.who.int/countries/484. Accessed June 5,
2024.
|
|
15
|
Huang DQ, Terrault NA, Tacke F, Gluud LL,
Arrese M, Bugianesi E and Loomba R: Global epidemiology of
cirrhosis-aetiology, trends and predictions. Nat Rev Gastroenterol
Hepatol. 20:388–398. 2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sarin SK, Kumar M, Eslam M, George J, Al
Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, et al:
Liver diseases in the Asia-Pacific region: A lancet
gastroenterology & hepatology commission. Lancet Gastroenterol
Hepatol. 5:167–228. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Barton JC, McLaren CE, Chen WP, Ramm GA,
Anderson GJ, Powell LW, Subramaniam VN, Adams PC, Phatak PD, Gurrin
LC, et al: Cirrhosis in hemochromatosis: Independent risk factors
in 368 HFE p.C282Y homozygotes. Ann Hepatol. 17:871–879.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gerosa C, Fanni D, Congiu T, Piras M, Cau
F, Moi M and Faa G: Liver pathology in Wilson's disease: From
copper overload to cirrhosis. J Inorg Biochem. 193:106–111.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Boonstra K, Beuers U and Ponsioen CY:
Epidemiology of primary sclerosing cholangitis and primary biliary
cirrhosis: A systematic review. J Hepatol. 56:1181–1188.
2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shah RA and Kowdley KV: Current and
potential treatments for primary biliary cholangitis. Lancet
Gastroenterol Hepatol. 5:306–315. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Puustinen L, Boyd S, Mustonen H, Arkkila
P, Arola J and Färkkilä M: Prognostic value of clinical variables
and liver histology for development of fibrosis and cirrhosis in
autoimmune hepatitis. Scand J Gastroenterol. 52:321–327.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lucey MR: Alcohol-associated cirrhosis.
Clin Liver Dis. 23:115–126. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Niu X, Zhu L, Xu Y, Zhang M, Hao Y, Ma L,
Li Y and Xing H: Global prevalence, incidence, and outcomes of
alcohol related liver diseases: A systematic review and
meta-analysis. BMC Public Health. 23(859)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li B, Zhang C and Zhan YT: Nonalcoholic
fatty liver disease cirrhosis: A review of its epidemiology, risk
factors, clinical presentation, diagnosis, management, and
prognosis. Can J Gastroenterol Hepatol.
2018(2784537)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Berumen J, Baglieri J, Kisseleva T and
Mekeel K: Liver fibrosis: Pathophysiology and clinical
implications. WIREs Mech Dis. 13(e1499)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kisseleva T: The origin of fibrogenic
myofibroblasts in fibrotic liver. Hepatology. 65:1039–1043.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zuñiga-Aguilar E and Ramírez-Fernández O:
Fibrosis and hepatic regeneration mechanism. Transl Gastroenterol
Hepatol. 7(9)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gross M: Hepatic cirrhosis: Early
diagnosis and prevention of complications. MMW Fortschr Med.
161:48–52. 2019.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
29
|
Zhang CY, Liu S and Yang M: Treatment of
liver fibrosis: Past, current, and future. World J Hepatol.
15:755–774. 2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Gillessen A and Schmidt HH: Silymarin as
supportive treatment in liver diseases: A narrative review. Adv
Ther. 37:1279–1301. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sumida Y, Yoneda M, Seko Y, Takahashi H,
Hara N, Fujii H, Itoh Y, Yoneda M, Nakajima A and Okanoue T: Japan
Study Group of NAFLD (JSG-NAFLD). Role of vitamin E in the
treatment of non-alcoholic steatohepatitis. Free Radic Biol Med.
177:391–403. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Li J and Tuo B: Current and emerging
approaches for hepatic fibrosis treatment. Gastroenterol Res Pract.
2021(6612892)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tacke F and Weiskirchen R: Non-alcoholic
fatty liver disease (NAFLD)/non-alcoholic steatohepatitis
(NASH)-related liver fibrosis: Mechanisms, treatment and
prevention. Ann Transl Med. 9(729)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hood SC, Moher D and Barber GG: Management
of intermittent claudication with pentoxifylline: Meta-analysis of
randomized controlled trials. CMAJ. 155:1053–1059. 1996.PubMed/NCBI
|
|
35
|
González-Pacheco H, Amezcua-Guerra LM,
Sandoval J and Arias-Mendoza A: Potential usefulness of
pentoxifylline, a non-specific phosphodiesterase inhibitor with
anti-inflammatory, anti-thrombotic, antioxidant, and
anti-fibrogenic properties, in the treatment of SARS-CoV-2. Eur Rev
Med Pharmacol Sci. 24:7494–7496. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Demircan V, Guzel C, Sarıbas GS, Dinc SC,
Cetin S, Gulbahar O, Erpolat P, Elmas C and Bora H: Evaluation of
therapeutic use of a combination of pentoxifylline and vitamin E in
radiation-induced renal fibrosis. Sci Rep. 14(6977)2024.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Taha H: Effect of pentoxifylline on
expression of proinflammatory cytokines. J Biotech Res. 12:23–32.
2021.
|
|
38
|
Pareek P, Sharma A, Thipparampalli JR, Nag
P, Gupta N, Shekhar S and Kirubakaran R: Pentoxifylline and vitamin
E alone or in combination for preventing and treating side effects
of radiation therapy and concomitant chemoradiotherapy. Cochrane
Database Syst Rev. 2016(CD012117)2016.
|
|
39
|
Zeng T, Zhang CL, Zhao XL and Xie KQ:
Pentoxifylline for the treatment of nonalcoholic fatty liver
disease: A meta-analysis of randomized double-blind,
placebo-controlled studies. Eur J Gastroenterol Hepatol.
26:646–653. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zein CO, Lopez R, Fu X, Kirwan JP, Yerian
LM, McCullough AJ, Hazen SL and Feldstein AE: Pentoxifylline
decreases oxidized lipid products in nonalcoholic steatohepatitis:
New evidence on the potential therapeutic mechanism. Hepatology.
56:1291–1299. 2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jiménez-Luévano M, Rodríguez-Chávez JL,
Ramírez-Flores S, Rodríguez-Villa P, Jiménez-Partida MÁ,
Cervantes-Rodríguez G, Hernández-Flores G, Solís-Martínez R and
Bravo-Cuellar A: Treatment of hepatocarcinoma with celecoxib and
pentoxifylline: A case report. Rev Med Inst Mex Seguro Soc.
56:309–315. 2018.PubMed/NCBI(In Spanish).
|
|
42
|
Tsoris A and Marlar CA: Use Of the child
pugh score in liver disease. StatPearls Publishing LLC, Treasure
Island, FL, 2024.
|
|
43
|
Zipprich A, Garcia-Tsao G, Rogowski S,
Fleig WE, Seufferlein T and Dollinger MM: Prognostic indicators of
survival in patients with compensated and decompensated cirrhosis.
Liver Int. 32:1407–1414. 2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Goldberg D, Mantero A, Kaplan D, Delgado
C, John B, Nuchovich N, Emanuel E and Reese PP: Accurate long-term
prediction of death for patients with cirrhosis. Hepatology.
76:700–711. 2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gines P, Quintero E, Arroyo V, Terés J,
Bruguera M, Rimola A, Caballería J, Rodés J and Rozman C:
Compensated cirrhosis: Natural history and prognostic factors.
Hepatology. 7:122–128. 1987.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Liu YB and Chen MK: Epidemiology of liver
cirrhosis and associated complications: Current knowledge and
future directions. World J Gastroenterol. 28:5910–5930.
2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Jiménez-Luévano MA, Ramírez-Flores S,
Sepúlveda-Castro R, Jiménez-Partida AE, Jiménez-Partida MÁ,
Ruiz-Mercado H, Cortés-Aguilar Y, Bravo-Cuellar A and
Hernández-Flores G: Fulminant hepatitis managed with
pentoxifylline. J Clin Exp Pharmacol. 10:1–6. 2020.
|
|
48
|
Angel MJL, Samuel RF, Paulina RV, Angel
MJP, Georgina HF and Alejandro BC: Management of hepatocarcinoma
with celecoxib and pentoxifylline: Report of three cases. J Clin
Exp Pharmacol. 8:1–6. 2018.
|
|
49
|
Jiménez-Luévano M, Lerma-Díaz JM,
Hernández-Flores G, Jiménez-Partida M and Bravo-Cuellar A: Addition
of pentoxifylline to pegylated interferon-alpha-2a and ribavirin
improves sustained virological response to chronic hepatitis C
virus: A randomized clinical trial. Ann Hepatol. 12:248–255.
2013.PubMed/NCBI
|
|
50
|
Wen WX, Lee SY, Siang R and Koh RY:
Repurposing pentoxifylline for the treatment of fibrosis: An
overview. Adv Ther. 34:1245–1269. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Das PP and Medhi S: Role of inflammasomes
and cytokines in immune dysfunction of liver cirrhosis. Cytokine.
170(156347)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
González-Espinoza L, Rojas-Campos E,
Medina-Pérez M, Peña-Quintero P, Gómez-Navarro B and Cueto-Manzano
AM: Pentoxifylline decreases serum levels of tumor necrosis factor
alpha, interleukin 6 and C-reactive protein in hemodialysis
patients: Results of a randomized double-blind, controlled clinical
trial. Nephrol Dial Transplant. 27:2023–2028. 2012.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Duman DG, Ozdemir F, Birben E, Keskin O,
Ekşioğlu-Demiralp E, Celikel C, Kalayci O and Kalayci C: Effects of
pentoxifylline on TNF-alpha production by peripheral blood
mononuclear cells in patients with nonalcoholic steatohepatitis.
Dig Dis Sci. 52:2520–2524. 2007.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Weiss JM, Vanscheidt W, Pilarski KA, Weyl
A, Peschen M, Schöpf E, Vestweber D and Simon JC: Pentoxifylline
inhibits tumor necrosis factor-α (TNF alpha)-induced T-lymphoma
cell adhesion to endothelioma cells. J Invest Dermatol.
104:824–828. 1995.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Akriviadis E, Botla R, Briggs W, Han S,
Reynolds T and Shakil O: Pentoxifylline improves short-term
survival in severe acute alcoholic hepatitis: A double-blind,
placebo-controlled trial. Gastroenterology. 119:1637–1648.
2000.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Oakley F, Gee LM, Sheerin NS and Borthwick
LA: Implementation of pre-clinical methodologies to study fibrosis
and test anti-fibrotic therapy. Curr Opin Pharmacol. 49:95–101.
2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Hepgül G, Tanrikulu S, Unalp HR, Akguner
T, Erbil Y, Olgaç V and Ademoğlu E: Preventive effect of
pentoxifylline on acute radiation damage via antioxidant and
anti-inflammatory pathways. Dig Dis Sci. 55:617–625.
2010.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Satapathy SK, Sakhuja P, Malhotra V,
Sharma BC and Sarin SK: Beneficial effects of pentoxifylline on
hepatic steatosis, fibrosis and necroinflammation in patients with
non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 22:634–638.
2007.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Assimakopoulos SF, Thomopoulos KC and
Labropoulou-Karatza C: Pentoxifylline: A first line treatment
option for severe alcoholic hepatitis and hepatorenal syndrome?
World J Gastroenterol. 15:3194–3195. 2009.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Van Wagner LB, Koppe SWP, Brunt EM,
Gottstein J, Gardikiotes K, Green RM and Rinella ME: Pentoxifylline
for the treatment of non-alcoholic steatohepatitis: A randomized
controlled trial. Ann Hepatol. 10:277–286. 2011.PubMed/NCBI
|
